BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, December 27, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 21, 2006

View Archived Issues

Bryostatin 1 provides protection against ischemia/reperfusion injury

Read More

Orally available novel nucleotide is active against drug-resistant HIV-1 mutants

Read More

Updated profile of ARD-353, a cardioprotective nonpeptide delta opioid receptor agonist

Read More

Tadalafil improves neurological function in a preclinical stroke model

Read More

Initial preclinical data for ReN-004 stem cell lines for Parkinson's disease

Read More

Three registrational phase III trials of Erbitux complete enrollment

Read More

New phase III trial studies Nexavar in NSCLC

Read More

17beta-Estradiol targets STAT3 to provide neuroprotection following stroke

Read More

Dana-Farber Cancer Institute to study CTCE-9908 for brain cancer

Read More

BioInvent reassigns rights to develop osteoarthritis drugs to Cartela

Read More

CFFT to continue support for Copernicus' gene therapy for cystic fibrosis

Read More

New studies suggest Ampligen and Alferon may protect against avian flu

Read More

NNZ-4921 shows promise in rat peripheral neuropathy model

Read More

Results of studies investigating AAGP effect on cellular growth and function

Read More

Orphan drug designation for Coramsine for melanoma

Read More

Targeting gamma-secretase provides neuroprotection in preclinical stroke

Read More

Novel compounds with possible utility in the treatment of cancer revealed

Read More

Preclinical and clinical data on JTK-303/GS-9137 disclosed

Read More

New therapeutic agents for acne disclosed in recent Galderma patent

Read More

Rho kinase inhibitors prepared and tested at GlaxoSmithKline

Read More

CD38-derived peptide shows potent anti-HIV-1 activity in vitro

Read More

New HIV protease inhibitor shows promise for multidrug-resistant HIV infection

Read More

Pilot bioavailability testing of CDT extended release ondansetron tablets

Read More

Vusion approved for treatment of diaper dermatitis complicated by candidiasis

Read More

Hycamtin sNDA accepted for priority review

Read More

Rimonabant receives approvable, nonapprovable letters

Read More

FDA approval for new oral contraceptive Loestrin 24 Fe

Read More

CE Mark for CoStar paclitaxel-eluting stent

Read More

Alvesco approved in Europe for mild to severe persistent asthma in adolescents

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing